Imedex: Education is the Best Medicine®

QUICK POLL

If imatinib, nilotinib, and dasatinib are all approved for front-line therapy of newly diagnosed chronic phase (CP) chronic myelogenous leukemia (CML), what would you recommend as front-line therapy for a 42-year-old man who presents with high-risk CML by both the Sokal and Hasford (Euro) scoring systems and who has no matched sibling donor?

15th Annual NOCR Meeting

March 13-14, 2009

Las Vegas, Nevada

Westin Casuarina Las Vegas Hotel

Continuing Medical Education

Imedex, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This activity has been approved for AMA PRA Category 1 Credit™.

Who Should Attend

This educational activity is specifically designed for oncologists, hematologists and other healthcare professionals (including nurses and pharmacists) interested and/or involved in the care of patients with cancer.

Objectives

After successful completion of this activity, participants should be able to:

Discuss recent clinical advances among a wide range of cancer disciplines as they relate to the therapeutic management of the disease
Describe and evaluate areas of clinical controversy in the management of various malignancies
Recommend treatment modalities and emerging therapeutic approaches based upon the assimilation of expert-guided case presentations
Discuss the clinical significance of targeted therapy in terms of complete response, prolonged survival and quality of life issues
Highlight therapeutic advances and clinical updates in orphan cancers such as sarcomas, melanomas, head and neck cancer, neuro-oncology and gynecological malignancies

Dean F. Bajorin, MD
Memorial Sloan-Kettering Cancer Center
New York, New York

Tracy T. Batchelor, MD, MPH
Massachusetts General Hospital
Boston, Massachusetts

Jorge Cortes, MD
The University of Texas MD Anderson Cancer Center
Houston, Texas

Christopher Crane, MD
The University of Texas MD Anderson Cancer Center
Houston, Texas

Myron Czuczman, MD
Roswell Park Cancer Institute
Buffalo, New York

James Epstein, MD
Imedex, LLC
Alpharetta, Georgia

Rafael Fonseca, MD
Mayo Clinic
Scottsdale, Arizona

Edward P. Gelmann, MD
Herbert Irving Comprehensive Cancer Center Columbia University Milstein
New York, New York

Ramaswamy Govindan, MD
Washington University School of Medicine
St. Louis, Missouri

Axel Grothey, MD
Mayo Clinic College of Medicine
Rochester, Minnesota

Tom Herzog, MD
Columbia University Medical Center
New York, New York

Tim Hobday, MD
Mayo Clinic Medical School
Rochester, Minnesota

David H. IIson, MD
Memorial Sloan-Kettering Cancer Center
New York, New York

John Kirkwood, MD
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania

Corey Langer, MD, FACP
Fox Chas Cancer Center
Philadelphia, Pennsylvania

Ruth O’Regan, MD
Emory University
Atlanta, Georgia

Robert Z. Orlowski, MD, PhD
The University of Texas MD Anderson Cancer Center
Houston, Texas

Shreyaskumar Patel, MD
The University of Texas MD Anderson Cancer Center
Houston, Texas

Mark Pegram, MD
University of Miami
Miami, Florida

Christy Russell, MD
University of Southern California
Los Angeles, California

Mark A. Socinski, MD
Lineberger Comprehensive Cancer Center Chapel Hill,
North Carolina

Deborah Toppmeyer, MD
The Cancer Institute of New Jersey
New Brunswick, New Jersey

Alan Venook, MD
USCF Medical Center
San Francisco, California

Nicholas J. Volgelzang, MD
Nevada Cancer Institute
Las Vegas, Nevada

Friday, March 13, 2009

7:00 am Breakfast

8:00 am Welcome and introduction

Session I: Keynote Address
Moderator: James Epstein, MD

8:10 am The importance of Ras mutations and their clinical significance in oncology
Alan Venook, MD

8:50 am Q & A

Session II: Gastrointestinal Cancers
Moderator: Axel Grothey, MD

9:00 am Personalized medicine for GI cancers: Are we there yet?
Axel Grothey, MD

9:25 am Combining EGFR and VEGF/VEGFR targeted therapies: Advantage or Adversity?
Alan Venook, MD

9:50 am Debate: The role of combined modality therapy in locally advanced pancreatic cancer
Christopher Crane, MD vs. David H. IIson, MD

10:15 am Coffee break

10:35 am Therapeutic advances in gastrointestinal neuroendocrine tumors
Tim Hobday, MD

11:00 am Case presentation & discussion
Case 1: Advanced CRC relapsed post FOL-FOX-bevacizumab
Case 2: Locally advanced adenocarcinoma of the GE junction
Moderator: Axel Grothey, MD
Panel: Christopher Crane, MD, Tim Hobday, MD and David H. IIson, MD

Session III: Breast Cancer
Moderator: Christy Russell, MD

11:25 am Management of bone related issues in breast cancer - Which therapy for which patient?
Christy Russell, MD

11:50 am Triple negative breast cancer: Advances in the epidemiology, genomics and management
Ruth O’Regan, MD

12:15 pm Lunch

1:15 pm Controversies & challenges in HER2 over-expressed breast cancer
Mark Pegram, MD

1:40 pm Case presentation & discussion
Case 1: Pre-menopausal woman with ER/PR+ node-negative breast cancer
Case 2: Relapsed metastatic HER2+ breast cancer
Moderator: Christy Russell, MD
Panel: Ruth O’Regan, MD, Mark Pegram, MD and Deborah Toppmeyer, MD

Session IV: Meet the Experts
2 Concurrent Sessions

2:05 pm Advances in the management of ER/PR+ breast cancer
Deborah Toppmeyer, MD

Evaluating and managing the older patient with acute leukemia
Jorge Cortes, MD

2:50 pm Coffee break

Session V: Hematologic Oncology
Moderator: Robert Z. Orlowski, MD, PhD

3:10 pm Advances in myeloproliferative disorders
Jorge Cortes, MD

3:35 pm Emerging therapies for lymphoproliferative disorders
Myron Czuczman, MD

4:00 pm Evidence based management algorithm for newly diagnosed transplant eligible multiple myeloma patients
Robert Z. Orlowski, MD, PhD

4:25 pm Meeting summary & adjourn

5:00 pm Evening reception

Saturday, March 14, 2009

7:00 am Breakfast

Session VI: Early Bird - Meet the Experts
2 Concurrent Sessions

7:10 am Stage III NSCLC: Putting clarity into heterogeneity
Mark A. Socinski, MD

Management strategies for the high risk myeloma patient
Rafael Fonseca, MD

8:00 am Introductions

Session VII: Lung Cancer
Moderator: James Epstein, MD

8:10 am Debate: Should patients undergo tumor testing for EGFR copy number, EGFR mutation status or Kras mutation status before receiving EGFR targeted therapy?
Corey Langer, MD, FACP vs. Mark A. Socinski, MD

8:35 am Small cell lung cancer: Is there any good news?
Ramaswamy Govindan, MD

9:00 am Novel agents in NSCLC
Ramaswamy Govindan, MD

9:25 am Case presentation & discussion
Case 1: Newly diagnosed advanced adenocarcinoma in a non-smoking female
Moderator: James Epstein, MD
Panel: Ramaswamy Govindan, MD, Corey Langer, MD, FACP and Mark A. Socinski, MD

9:50 am Coffee break

Session VIII: Mini-Symposium: Advances in Orphan Cancers
Moderator: Christy Russell, MD

10:10 am Emerging therapies for GYN malignancies
Tom Herzog, MD

10:35 am Clinical update in management of soft tissue sarcomas
Shreyaskumar Patel, MD

11:00 am Advances in the management of malignant melanoma
John Kirkwood, MD

11:25 am Head & neck cancers: Recent advances in management
Corey Langer, MD, FACP

12:00 pm Clinical update on neuro-oncology
Tracy T. Batchelor, MD, MPH

12:25 pm Lunch

Session IX: Genitourinary Cancer
Moderator: Dean F. Bajorin, MD

2:00 pm Emerging novel therapies for hormone refractory prostate cancer
Edward P. Gelmann, MD

2:25 pm Triumphs and cautions in the management of advanced renal cell carcinoma
Nicholas J. Volgelzang, MD

3:00 pm Case presentation & discussion
Case 1: Newly diagnosed high risk advanced RCC
Case 2: Relapsed metastatic RCC post-sunitinib therapy
Case 3: T3 TCC of bladder:
neoadjuvant therapy or resection
plus adjuvant therapy
Moderator: Edward Gelmann, MD and Nicholas J. Volgelzang, MD

3:25 pm Meeting summary & adjourn

Registration Fees
Physicians . . . . . . . . . . . . . . . . . . . . $125.00

Nurses, Students and Fellows* . . . . . . $75.00
*Proof of eligibility must accompany registration

To Register: You may register online by March 5, 2009 or by calling Imedex at +1 (678) 242 0906. Registration confirmations will be issued before the meeting.

Payment: To pre-register, registration and payment must be received no later than March 5, 2009. Please register onsite after this date. Contact Imedex at +1 (678) 242 0906 or visit our website at www.imedex.com to ensure the course is being held as scheduled and to confirm that the meeting is not full. Registration fees must be remitted by credit card or check. Checks should be payable to Imedex. Attendee is not registered until full payment is received.

Registration Fee Inclusions: Registration fees include admittance to all scientific sessions, conference materials, processing of certificates of attendance or continuing medical education, and all event functions as specified in the announcement.

Cancellation: For registration fees to be refunded, written notice of cancellation must be received at meetings@imedex.com no later than March 5, 2009. The amount of registration fees remitted, minus a $50 administrative charge, will be refunded after the conference. Substitutions are accepted with written notification. No refunds will be made if notice is received after March 5, 2009.

Imedex does not accept responsibility for covering travel, accommodation or any other costs incurred by registrants in the rare event that this meeting should be canceled for any reason. Every effort will be made to give reasonable notice in the event of cancellation. The event agenda is subject to change without notice.

The Westin Casuarina
160 E. Flamingo Road
Las Vegas, Nevada 89109
Tel.: +1 (702) 836 5900
Fax: +1 (702) 836 9776

Stay at The Westin Casuarina Las Vegas Hotel for a calm sanctuary amidst the bustle of Las Vegas. You’ll enjoy the action and excitement of the famous “Strip” just one block away—and a quiet retreat whenever you need some peace. In a city known for glitz and glamour, the 826 guest rooms and suites offer understated style and the utmost elegance. Muted tones, soft lighting, and simple contemporary decor create an environment where you can’t help but feel at ease.

For the convenience of attendees, a limited number of rooms have been reserved until Friday, February 20, 2009 at a discounted rate of $159.00 single or double occupancy, plus state and local taxes, currently at 9% and the resort service fee of $10.00 per room per day plus tax. This rate is not guaranteed outside the conference dates or after Friday, February 20, 2009.
To reserve your room please contact the Westin Casuarina reservations department at +1 (702) 836 5900 or visit the hotel’s website at http://www.starwoodmeeting.com/StarGroupsWeb/res?id=0810249018&key=E2428. To receive the group rate, callers must identify themselves as being with the NOCR Annual Meeting group. Reservation requests received after Friday, February 20, 2009 may not be guaranteed the group rate.

All reservations must be accompanied by a first night room deposit or guaranteed with a major credit card. The Hotel will not hold any reservation unless secured by one of the above methods.Cancellations received within forty-eight (48) hours prior to arrival will be charged a cancellation fee equal to one (1) night’s room revenue and tax.

In the event a guest checks out before the reserved check-out date, an early departure fee of $75.00 will be charge. Guests wishing to avoid this fee must advise the Hotel at or before check-in of any change in the scheduled length of stay.

ORGANIZER

Imedex
4325 Alexander Drive
Alpharetta, GA 30022-3740 USA
Tel.: +1 (770) 751 7332
Fax: +1 (770) 751 7334
Email: meetings@imedex.com
Web: www.imedex.com

Imedex is a brand and assumed name used by Imedex, LLC (hereby referred to as Imedex). Imedex is solely responsible for this agenda’s content. Although Imedex attempts to ensure that the information in our program is accurate and timely, matters and opinions discussed and/or presented with respect to clinical matters are those of the discussion participants only, and not necessarily those of Imedex. Moreover, although Imedex attempts to identify and integrate the most qualified medical professionals in our program, TO THE FULLEST EXTENT PERMITTED BY LAW, IMEDEX EXPRESSLY DISCLAIM ALL WARRANTIES, EITHER EXPRESS OR IMPLIED, STATUTORY OR OTHERWISE, INCLUDING BUT NOT LIMITED TO THE IMPLIED WARRANTIES OF MERCHANTABILITY, NON-INFRINGEMENT OF THIRD PARTIES’ RIGHTS, AND FITNESS FOR A PARTICULAR PURPOSE, WITH RESPECT TO THE CONTENT PRESENTED. IMEDEX FURTHER MAKES NO REPRESENTATIONS OR WARRANTIES ABOUT THE ACCURACY, RELIABILITY, COMPLETENESS OR TIMELINESS OF THE CONTENT OR ANY MATERIAL PRESENTED.

In addition, the material presented and related discussions are not intended to be medical advice, and the presentation or discussion of such material is not intended to create and does not establish a physician-patient relationship. Medical advice of any nature should be sought from an individual’s own physician.

Neither Imedex nor any of its subsidiaries or affiliates is affiliated with or formally endorsed by a medical society.

PLATINUM

Genentech BioOncology

GOLD

SILVER

BRONZE

eisai

Millennium Pharmaceuticals, Inc.

Several options are available to companies interested in supporting this Congress. For more information, please contact Imedex at +1(770) 751 7332, or by email at cme@imedex.com.